Gilead Sciences (GILD.US) announced that it had struck a licensing agreement to produce the antiviral drug remdesivir in 127 countries, not including the US. The company’s will work with five generic drugmakers to produce the potential drug for coronavirus. Among them is Mylan (MYL.US), which is the world's largest producer of generic drugs.

Gilead Sciences (GILD.US) shares rose 1.96% in pre-market trading. If positive mood persists, then resistance at $86.16 per share may be tested. Source: xStation5
Stock of the Week: Seagate Technology. How an old technology found a new role in the era of artificial intelligence
US Open: Wall Street rebounds as AI and semiconductors overshadow Iran concerns
Everything You Need to Know About the Upcoming Earnings Season⏰
Defense stocks fall after NATO Summit 🚩 Rheinmetall drops 4%, KNDS suspends IPO